Novartis Ag ADR
(NY:
NVS
)
113.95
+0.18 (+0.16%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
820,384
Open
112.88
Bid (Size)
113.00 (3)
Ask (Size)
116.23 (1)
Prev. Close
113.77
Today's Range
112.80 - 114.03
52wk Range
92.19 - 120.92
Shares Outstanding
N/A
Dividend Yield
3.04%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
Via
Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Performance
YTD
+12.82%
+12.82%
1 Month
-2.18%
-2.18%
3 Month
+5.45%
+5.45%
6 Month
+19.34%
+19.34%
1 Year
+17.30%
+17.30%
More News
Read More
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
October 03, 2024
Via
Investor's Business Daily
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
September 13, 2024
Via
Chartmill
NYSE:NVS: good value for what you're paying.
September 03, 2024
Via
Chartmill
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The Importance of Managing Bad Cholesterol: What You Should Know
September 27, 2024
Via
Brandpoint
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
Via
FinancialNewsMedia
Exposures
Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
Via
FinancialNewsMedia
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Via
Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
Via
Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
September 11, 2024
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
Via
Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
Via
Benzinga
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
September 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
August 28, 2024
Via
Benzinga
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
August 28, 2024
From
Lindy Biosciences
Via
Business Wire
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
August 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
August 26, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.